Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone
Source: SeekingAlpha
2026-03-12 20:02:58 ET
More on Capricor Therapeutics, Inc.
- Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
- Capricor Therapeutics: A High Risk/High Reward Name
- Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
- Capricor Therapeutics, Inc. Q4 2025 Earnings Preview
- Capricor extends rally as FDA to review rejected cell therapy
Read the full article on Seeking Alpha
For further details see:
Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone
Capricor Therapeutics Inc.
NASDAQ: CAPR
CAPR Trading
-7.11% G/L:
$30.885 Last:
619,824 Volume:
$33 Open:
CAPR Latest News
CAPR Stock Data
$1,278,443,622
46,286,693
0.54%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
